Iovance Biotherapeutics Inc (IOVA : NASDAQ)
Common Stock
$14.62
USD
+1.31 (9.84%)
Last updated: 2026-10-09
Follow IOVA
IOVA
Iovance Biotherapeutics Inc
WealthAwesomePerformance
1 Day
+9.84%
1 Week
+2.81%
1 Month
+73.43%
YTD
+272.01%
Key Statistics
Market Cap
$6.62B
52W High
$15.30
52W Low
$1.76
P/E Ratio
-
50 Day MA
$9.15
200 Day MA
$5.01
Beta
0.76
Dividend Yield
-
Advertisement
Technical Indicators
Price vs 50-Day SMA
Price vs 200-Day SMA
Recent Price History
| Date | Open | High | Low | Close | Adj Close | Volume |
|---|---|---|---|---|---|---|
| 10/9/2026 | $13.36 | $14.94 | $13.29 | $14.62 | $14.62 | 16,970,400 |
| 10/8/2026 | $12.64 | $13.39 | $12.62 | $13.31 | $13.31 | 14,802,496 |
| 10/7/2026 | $12.52 | $13.15 | $12.31 | $12.91 | $12.91 | 14,516,729 |
| 10/6/2026 | $14.21 | $14.21 | $12.92 | $12.96 | $12.96 | 18,895,400 |
| 10/5/2026 | $14.03 | $14.40 | $13.71 | $14.15 | $14.15 | 11,709,841 |
| 10/2/2026 | $14.45 | $14.75 | $13.95 | $14.22 | $14.22 | 11,914,800 |
| 10/1/2026 | $14.70 | $15.03 | $14.19 | $14.23 | $14.23 | 15,948,341 |
| 9/30/2026 | $14.65 | $15.11 | $14.10 | $14.82 | $14.82 | 29,299,343 |
| 9/29/2026 | $12.79 | $15.30 | $12.78 | $14.45 | $14.45 | 77,401,877 |
| 9/28/2026 | $10.88 | $11.16 | $10.68 | $10.99 | $10.99 | 12,206,194 |
Analyst Price Targets
Based on 10 analysts covering IOVA · as of Oct 12, 2026
Wall Street analysts forecast IOVA stock price to fall 9.0% over the next 12 months.
Consensus
Buy4.40 / 5.00
Avg. Target
US$13.30
-9.0% Upside
Previously US$12.80 on Oct 5, 2026
Current Price
US$14.62
Last close
Analyst Breakdown (10 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on IOVA's historical volatility
30-Day Vol
97.4%
Annualized
90-Day Vol
111.4%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
US$17.48
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | US$15.52 | US$11.09 – US$21.71 |
| 60 trading days | US$16.47 | US$10.24 – US$26.48 |
| 90 trading days | US$17.48 | US$9.77 – US$31.28 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
About Iovance Biotherapeutics Inc
Iovance Biotherapeutics, Inc., a commercial-stage biopharmaceutical company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States and internationally. The company offers Amtagvi, an individualized T cell therapy for solid tumor cancer and for the treatment of adult patients with previously treated advanced, or unresectable or metastatic melanomal; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic melanoma and metastatic renal cell carcinoma. It also develops lifileucel for the treatment of melanoma, cervical cancer, non-small cell lung cancer (NSCLC), endometrial cancer, and head and neck squamous cell carcinoma (HNSCC); LN-145-S1 to treat melanoma and HNSCC; LN-145 Gen 3 and core biopsy for the treatment of NSCLC; LN-145 Gen 3 to treat melanoma and HNSCC; IOV-2001 to treat chronic lymphocytic leukemia and small lymphocytic lymphoma; IOV-4001 for the treatment of melanoma and NSCLC; and IOV-3001 for use in the TIL therapy treatment regimen. The company has collaborations and licensing agreements with National Institutes of Health; the National Cancer Institute; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.
Financials
- Revenue (TTM)
- $324.97M
- EBITDA
- $-259.60M
- Profit Margin
- -89.09%
- ROE (TTM)
- -40.36%
- EPS (Diluted)
- -0.69
- Book Value
- 1.63
Classification
- Sector
- Health Care
- Industry
- Biotechnology
- Group
- Pharmaceuticals, Biotechnology & Life Sciences
7 stocks to buy and hold forever
Blue-chip dividend stocks for long-term wealth building.
Get the FREE ReportExplore More
Advertisement
Common Questions About IOVA.US
Market movers
Recent NASDAQ movers
Top 1-day gainers — updated from our Canadian movers feed.
| Ticker | Name | Price | 1D |
|---|---|---|---|
| DFLI | Dragonfly Energy Holdings Corp. | $3.72 | +658.88% |
| WFF | WF Holding Limited Ordinary Shares | $12.29 | +499.51% |
| ILLR | Triller Group Inc. Common Stock | $0.08 | +100.97% |
| JZ | Jianzhi Education Technology Group Company Limited American Depositary Shares | $1.28 | +53.48% |
| ZYBT | Zhengye Biotechnology Holding Limited Ordinary Shares | $1.73 | +50.45% |
| VEEA | Veea Inc. | $5.70 | +47.29% |
| QETA | Quetta Acquisition Corporation Common Stock | $16.41 | +41.47% |
| PDSB | PDS Biotechnology Corp | $1.38 | +35.29% |
IOVA.US news timeline
1 article covering IOVA.US, most recent first
Latest